These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 8698676)
21. Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Niwa T; Maekawa Y; Fujimoto M; Kishimoto K; Yabusaki Y; Ishibashi F; Katagiri M Biol Pharm Bull; 2002 Feb; 25(2):235-8. PubMed ID: 11853173 [TBL] [Abstract][Full Text] [Related]
22. Are pharmacokinetic drug interactions with the SSRIs an issue? Brøsen K Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():23-7. PubMed ID: 8732441 [TBL] [Abstract][Full Text] [Related]
23. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Barecki ME; Casciano CN; Johnson WW; Clement RP Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723 [TBL] [Abstract][Full Text] [Related]
24. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Mitchell PB Drug Saf; 1997 Dec; 17(6):390-406. PubMed ID: 9429838 [TBL] [Abstract][Full Text] [Related]
25. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. Kobayashi K; Yamamoto T; Chiba K; Tani M; Ishizaki T; Kuroiwa Y Br J Clin Pharmacol; 1995 Nov; 40(5):481-5. PubMed ID: 8703653 [TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 isozymes and antiepileptic drug interactions. Levy RH Epilepsia; 1995; 36 Suppl 5():S8-13. PubMed ID: 8806399 [TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141 [TBL] [Abstract][Full Text] [Related]
28. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Damkier P; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487 [TBL] [Abstract][Full Text] [Related]
29. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Crespi CL; Penman BW Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176 [TBL] [Abstract][Full Text] [Related]
30. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160 [TBL] [Abstract][Full Text] [Related]
31. Drug interactions with newer antidepressants: role of human cytochromes P450. Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI J Clin Psychiatry; 1998; 59 Suppl 15():19-27. PubMed ID: 9786307 [TBL] [Abstract][Full Text] [Related]
32. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802 [TBL] [Abstract][Full Text] [Related]
33. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916 [TBL] [Abstract][Full Text] [Related]
34. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129 [TBL] [Abstract][Full Text] [Related]
35. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Caccia S Clin Pharmacokinet; 1998 Apr; 34(4):281-302. PubMed ID: 9571301 [TBL] [Abstract][Full Text] [Related]
36. Drug metabolism and variability among patients in drug response. Wilkinson GR N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386 [No Abstract] [Full Text] [Related]
37. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Damkier P; Brøsen K Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551 [TBL] [Abstract][Full Text] [Related]
38. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031 [TBL] [Abstract][Full Text] [Related]
39. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Frye RF; Branch RA Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639 [TBL] [Abstract][Full Text] [Related]
40. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]